目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 40)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CLINICAL TRIALS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 44)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2021-2026
FIGURE 8 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 56)
FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION)
FIGURE 13 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION)
FIGURE 14 CLINICAL TRIALS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 15 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET

4 PREMIUM INSIGHTS (Page No. - 60)
4.1 CLINICAL TRIALS MARKET OVERVIEW
FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH
4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020)
FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2020
4.3 CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICE TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 63)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing investment in pharmaceutical R&D
FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2026
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2021
5.2.1.2 Increasing number of clinical trials
FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2021)
5.2.1.3 High cost of in-house drug development
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
5.2.1.4 Rising prevalence of orphan and rare diseases
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001-2020)
TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020
5.2.2.2 Rising demand for specialized testing services among end users
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals for clinical trials
5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules
5.2.4 MARKET TRENDS
5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery
5.2.4.2 Increasing outsourcing activities in emerging Asian economies
5.2.4.3 Integrated end-to-end R&D service solutions
5.3 RANGES/SCENARIOS
FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET
5.4 IMPACT OF COVID-19 ON CLINICAL TRIALS MARKET
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 DEGREE OF COMPETITION
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
5.7 ECOSYSTEM ANALYSIS
FIGURE 28 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET
TABLE 4 SUPPLY CHAIN ECOSYSTEM
5.8 REGULATORY ANALYSIS

6 CLINICAL TRIALS MARKET, BY PHASE (Page No. - 82)
6.1 INTRODUCTION
TABLE 5 CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION
FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING
6.3 PHASE I
6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT
TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS
TABLE 7 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 8 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 9 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
6.4 PHASE II
6.4.1 LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS
TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 12 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 13 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 14 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 15 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
6.5 PHASE III
6.5.1 RISING COSTS OF PHASE III TRIALS INCREASES THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES
TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY
TABLE 17 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 18 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 19 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 20 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
6.6 PHASE IV
6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 23 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 24 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 25 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)

7 CLINICAL TRIALS MARKET, BY SERVICE TYPE (Page No. - 97)
7.1 INTRODUCTION
TABLE 26 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
7.2 PROTOCOL DESIGNING
7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES
TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.3 SITE IDENTIFICATION
7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY
TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.4 PATIENT RECRUITMENT
7.4.1 GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT
TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS
TABLE 36 PATIENT RECRUITEMENT MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 37 NORTH AMERICA: PATIENT RECRUITEMENT MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 38 EUROPE: PATIENT RECRUITEMENT MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 39 ASIA PACIFIC: PATIENT RECRUITEMENT MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.5 LABORATORY SERVICES
7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT
TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.5.2 ANALYTICAL TESTING SERVICES
7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment
TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6 BIOANALYTICAL TESTING SERVICES
7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD BILLION)
TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.2 CELL-BASED ASSAYS
7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment
TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.3 VIROLOGY TESTING
7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment
TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES
7.6.4.1 Rising importance of studies to determine pharmacokinetic behavior of drug candidates to drive the growth of this segment
TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION
7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment
TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES
7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth
TABLE 70 SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.7 BIOMARKER TESTING SERVICES
7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth
TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.6.8 OTHER BIOANALYTICAL TESTING SERVICES
TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES
7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.9 DECENTRALIZED CLINICAL TRIAL SERVICES
7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS
TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.10 MEDICAL DEVICE TESTING SERVICES
7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET
TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
7.11 OTHER CLINICAL TRIAL SERVICES
7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES
TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2019-2026 (USD BILLION)
TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD BILLION)

8 CLINICAL TRIALS MARKET, BY THERAPY AREA (Page No. - 135)
8.1 INTRODUCTION
TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
8.2 ONCOLOGY
8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020)
FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND)
TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 105 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD BILLION)
TABLE 106 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 107 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 108 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
8.3 INFECTIOUS DISEASES
8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD BILLION)
TABLE 110 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 111 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 112 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
8.4 NEUROLOGY
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 114 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION, 2019-2026 (USD BILLION)
TABLE 115 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 116 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 117 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
8.5 IMMUNOLOGY
8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES
TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 2019-2026 (USD BILLION)
TABLE 119 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 120 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 121 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
8.6 CARDIOLOGY
8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 123 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION, 2019-2026 (USD BILLION)
TABLE 124 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 125 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 126 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019-2026 (USD BILLION)
8.7 GENETIC DISEASES
8.7.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH
TABLE 127 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION, 2019-2026 (USD BILLION)
TABLE 128 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 129 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 130 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019-2026 (USD BILLION)
8.8 WOMEN’S HEALTH
8.8.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE MARKET GROWTH
TABLE 131 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION, 2019-2026 (USD BILLION)
TABLE 132 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 133 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 134 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019-2026 (USD BILLION)
8.9 OTHER THERAPY AREAS
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
TABLE 136 CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2019-2026 (USD BILLION)
TABLE 137 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 138 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 139 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019-2026 (USD BILLION)

9 CLINICAL TRIALS MARKET, BY APPLICATION (Page No. - 156)
9.1 INTRODUCTION
TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
9.2 SMALL MOLECULE
9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS THE GROWTH OF THIS SEGMENT
FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019
TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 2019-2026 (USD BILLION)
TABLE 142 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 143 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019-2026 (USD BILLION)
9.3 VACCINES
9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON THE INDUSTRY OPERATIONS
FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT, BY PHASE (AS OF JANUARY 2022)
TABLE 145 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION, 2019-2026 (USD BILLION)
TABLE 146 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 147 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 148 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019-2026 (USD BILLION)
9.4 CELL & GENE THERAPY
9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND THEIR RESPECTIVE OFFERINGS IS DRIVING THE CLINICAL DEVELOPMENT PIPELINE FOR CELL & GENE THERAPY
FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY INDICATION (AS OF 2020)
FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020)
TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 2019-2026 (USD BILLION)
TABLE 150 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 151 EUROPE: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 152 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019-2026 (USD BILLION)
9.5 OTHER APPLICATIONS
9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH
TABLE 153 CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019-2026 (USD BILLION)
TABLE 154 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 155 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 156 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD BILLION)

10 CLINICAL TRIALS MARKET, BY REGION (Page No. - 168)
10.1 INTRODUCTION
TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 2019-2026 (USD BILLION)
10.2 NORTH AMERICA
FIGURE 38 NORTH AMERICA SNAPSHOT
TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 159 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 163 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.2.1 US
10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth
FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 165 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 166 US: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 167 US: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 168 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.2.2 CANADA
10.2.2.1 Increasing number of clinical trials in Canada to support market growth
TABLE 169 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 171 CANADA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 172 CANADA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 173 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3 EUROPE
FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 175 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 176 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 177 EUROPE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 178 EUROPE: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 179 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3.1 GERMANY
10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 181 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 182 GERMANY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 183 GERMANY: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 184 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3.2 UK
10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth
FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017 (USD MILLION)
TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 186 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 187 UK: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 188 UK: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 189 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3.3 FRANCE
10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France
TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 191 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 192 FRANCE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 193 FRANCE: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 194 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3.4 ITALY
10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth
TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 197 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 198 ITALY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 199 ITALY: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 200 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3.5 SPAIN
10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials in Spain
FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011-2017
TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 202 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 203 SPAIN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 204 SPAIN: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 205 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.3.6 REST OF EUROPE (ROE)
TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 207 ROE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 208 ROE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 209 ROE: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 210 ROE: CLINICAL TRIALS MARKET, BY MOLECULE, 2019-2026 (USD BILLION)
10.4 ASIA PACIFIC (APAC)
FIGURE 43 ASIA PACIFIC SNAPSHOT
TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY, 2019-2026 (USD BILLION)
TABLE 212 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 213 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 214 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 215 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 216 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.4.1 CHINA
10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and presence of prominent clinical trial service providers
TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 218 CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 219 CHINA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 220 CHINA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 221 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.4.2 JAPAN
10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth
TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 224 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 225 JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 226 JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 227 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.4.3 INDIA
10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trails
TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 230 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 231 INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 232 INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 233 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 236 ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 237 ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 238 ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 239 ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.5 LATIN AMERICA
10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET GROWTH IN LATIN AMERICA
TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 241 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 242 LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 243 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 244 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA
TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019-2026 (USD BILLION)
TABLE 246 MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019-2026 (USD BILLION)
TABLE 247 MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019-2026 (USD BILLION)
TABLE 248 MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019-2026 (USD BILLION)
TABLE 249 MEA: CLINICAL TRIALS MARKET, BY APPLICATION, 2019-2026 (USD BILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 224)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED
11.3 MARKET SHARE ANALYSIS
FIGURE 45 CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
11.4 COMPANY EVALUATION QUADRANT
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 46 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020
11.5 COMPETITIVE BENCHMARKING
11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET
11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 SERVICES LAUNCHES
TABLE 250 CLINICAL TRIALS MARKET: SERVICE LAUNCHES JANUARY 2017-NOVEMBER 2020)
11.6.2 DEALS
TABLE 251 CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021)
11.6.3 OTHER DEVELOPMENTS
TABLE 252 CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020)

12 COMPANY PROFILES (Page No. - 235)
12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 IQVIA
TABLE 253 IQVIA: BUSINESS OVERVIEW
FIGURE 49 IQVIA: COMPANY SNAPSHOT
TABLE 254 IQVIA: SERVICE OFFERINGS
TABLE 255 IQVIA: SERVICE LAUNCHES
TABLE 256 IQVIA: DEALS
TABLE 257 IQVIA: OTHER DEVELOPMENTS
12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE)
TABLE 258 LABCORP: BUSINESS OVERVIEW
FIGURE 50 LABCORP: COMPANY SNAPSHOT
TABLE 259 LABCORP: SERVICE OFFERINGS
TABLE 260 LABCORP: SERVICE LAUNCHES
TABLE 261 LABCORP: DEALS
TABLE 262 LABCORP: EXPANSIONS
12.1.3 SYNEOS HEALTH INC.
TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS
TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES
TABLE 266 SYNEOS HEALTH INC.: DEALS
12.1.4 WUXI APPTEC
TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT
TABLE 268 WUXI APPTEC: SERVICE OFFERINGS
TABLE 269 WUXI APPTEC: SERVICE LAUNCHES
TABLE 270 WUXI APPTEC: DEALS
TABLE 271 WUXI APPTEC: EXPANSIONS
12.1.5 CHARLES RIVER LABORATORIES
TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
TABLE 274 CHARLES RIVER LABORATORIES: DEALS
TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS
12.1.6 PAREXEL INTERNATIONAL
TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
TABLE 279 PAREXEL INTERNATIONAL: DEALS
TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS
12.1.7 PRA HEALTH SCIENCES
TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS
TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES
TABLE 284 PRA HEALTH SCIENCES: DEALS
TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS
12.1.8 PPD INC
TABLE 286 PPD INC: BUSINESS OVERVIEW
FIGURE 55 PPD INC: COMPANY SNAPSHOT
TABLE 287 PPD INC: SERVICE OFFERINGS
TABLE 288 PPD: SERVICE LAUNCHES
TABLE 289 PPD: DEALS
TABLE 290 PPD: EXPANSIONS
12.1.9 ICON PLC
TABLE 291 ICON PLC: BUSINESS OVERVIEW
FIGURE 56 ICON PLC: COMPANY SNAPSHOT
TABLE 292 ICON PLC: SERVICE OFFERINGS
TABLE 293 ICON PLC : SERVICE LAUNCHES
TABLE 294 ICON PLC: DEALS
12.1.10 MEDPACE HOLDINGS INC
TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
TABLE 297 MEDPACE HOLDINGS INC: DEALS
TABLE 298 MEDPACE HOLDINGS INC: EXPANSION
12.1.11 ACM GLOBAL LABORATORIES
TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS
12.1.12 ADVANCED CLINICAL
TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW
TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS
12.1.13 SGS
TABLE 303 SGS: BUSINESS OVERVIEW
FIGURE 58 SGS: COMPANY SNAPSHOT
TABLE 304 SGS: SERVICE OFFERINGS
TABLE 305 SGS: DEALS
12.1.14 FRONTAGE HOLDINGS CORPORATION
TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS
TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION
12.1.15 PSI CRO AG
TABLE 310 PSI CRO AG: BUSINESS OVERVIEW
TABLE 311 PSI CRO AG: SERVICE OFFERINGS
TABLE 312 PSI CRO AG: EXPANSIONS
12.1.16 BIO AGILE THERAPEUTICS
TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 AZELIX
TABLE 315 AZELIX: COMPANY OVERVIEW
12.2.2 CTSERV
TABLE 316 CTSERV: COMPANY OVERVIEW
12.2.3 PEPGRA
TABLE 317 PEPGRA: COMPANY OVERVIEW
12.2.4 AXCENT ADVANCED ANALYTICS (A3)
TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
12.2.5 DOVE QUALITY SOLUTIONS
TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW
12.2.6 FIRMA CLINICAL RESEARCH
TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
12.2.7 CELERION
TABLE 321 CELERION: COMPANY OVERVIEW
12.2.8 NOVOTECH HEALTH HOLDINGS
TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW
12.2.9 GENETICIST INC.
TABLE 323 GENETICIST INC.: COMPANY OVERVIEW
12.2.10 LINICAL AMERICAS
TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW

13 APPENDIX (Page No. - 310)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORT
13.5 AUTHOR DETAILS